Compare STLA & ZBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STLA | ZBH |
|---|---|---|
| Founded | 2021 | 1927 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.9B | 16.0B |
| IPO Year | 2014 | 2001 |
| Metric | STLA | ZBH |
|---|---|---|
| Price | $5.81 | $87.32 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 21 |
| Target Price | $11.59 | ★ $101.00 |
| AVG Volume (30 Days) | ★ 18.1M | 2.1M |
| Earning Date | 02-26-2026 | 04-28-2026 |
| Dividend Yield | ★ 7.50% | 1.20% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.22 |
| Revenue | N/A | ★ $8,231,500,000.00 |
| Revenue This Year | $7.18 | $4.96 |
| Revenue Next Year | $3.50 | $3.76 |
| P/E Ratio | ★ N/A | $71.73 |
| Revenue Growth | N/A | ★ 7.20 |
| 52 Week Low | $5.56 | $79.12 |
| 52 Week High | $12.22 | $108.29 |
| Indicator | STLA | ZBH |
|---|---|---|
| Relative Strength Index (RSI) | 33.41 | 49.81 |
| Support Level | N/A | $85.50 |
| Resistance Level | $8.30 | $96.69 |
| Average True Range (ATR) | 0.21 | 2.43 |
| MACD | -0.04 | -0.30 |
| Stochastic Oscillator | 17.82 | 38.98 |
Stellantis was created out of the merger of US-based Fiat Chrysler Automobiles and French-based Peugeot in January 2021, resulting in the fourth-largest automotive original equipment manufacturer by vehicle sales. In 2024, it sold 5.5 million vehicles, 47%, 26%, and 17% in Europe, North America, and South America, respectively. Its brands include Fiat, Jeep, Chrysler, Ram, Peugeot, Citroën, Opel, Alfa Romeo, and Maserati.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.